Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04502095 | Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy | completed | Phase 4 | 89 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2026 |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT03093922 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT07024680 | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC) | completed | — | 48 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04489771 | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | completed | Phase 2 | 154 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | completed | Early Phase 1 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07827482 | Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma | completed | — | 228 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01352962 | Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07821775 | Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers | completed | — | 32,949 | Asan Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05432232 | The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy(CAIN) | completed | N/A | 20 | HistoSonics, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05877820 | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC | completed | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02675829 | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | completed | Phase 2 | 131 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01261728 | Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02657486 | BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder | completed | N/A | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 35 | Inovio PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07798479 | Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study(IATREP_NMIBC) | completed | — | 64 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT03948724 | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology(EDHITO) | completed | N/A | 412 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04090710 | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer(CYTOSHRINK) | completed | Phase 2 | 66 | Ontario Clinical Oncology Group (OCOG)OTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03258593 | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | completed | Phase 2 | 31 | CatalYm GmbHINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03782207 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice(IMreal) | completed | — | 2,756 | Hoffmann-La RocheINDUSTRY | 30 | Aug 13, 2026 | clinicaltrials |
| NCT03587662 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06412848 | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | completed | — | 360 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03470285 | Multiparametric MRI for Diagnosing Small Renal Tumors(IRMK01) | completed | N/A | 387 | University Hospital, BordeauxOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT00458536 | Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF | completed | Phase 1 / Phase 2 | 36 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 | Jul 24, 2026 | clinicaltrials |
| NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)(KEYNOTE-866) | completed | Phase 3 | 907 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT04081246 | Transurethral Modified En Bloc Resection For Large Bladder Tumours. | completed | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 | Jul 21, 2026 | clinicaltrials |
| NCT07713654 | Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct Radiological-histopathological Correlation: an Explorative Study | completed | N/A | 9 | University of ZurichOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06955910 | Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies. | completed | — | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03345563 | Project HERO: Health Empowerment & Recovery Outcomes(HERO) | completed | N/A | 113 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04718584 | the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | completed | Phase 2 | 27 | Dragonboat Biopharmaceutical Company LimitedINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00403169 | Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Jul 2, 2026 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials